Metffil G2 Tablet PR contains a combination of Glimepiride (2mg) and Metformin (500mg), indicated for the management of type 2 diabetes mellitus, particularly in patients inadequately controlled on diet and exercise alone. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta-cell insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, enhancing glucose uptake and utilization. The combination therapy provides complementary mechanisms to achieve better glycemic control. Metffil G2 Tablet PR is typically prescribed as part of a comprehensive diabetes management plan, including diet modification and physical activity. It is important to monitor blood glucose levels regularly to adjust dosage and avoid hypoglycemia, a potential adverse effect associated with sulfonylureas. Metformin is generally well tolerated but may cause gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort. Rarely, lactic acidosis may occur, necessitating caution in patients with renal impairment or other contraindications. This fixed-dose combination offers improved patient compliance by reducing pill burden. Prior to initiation, renal function assessment and periodic monitoring during therapy are recommended. Metffil G2 Tablet PR should be used under medical supervision, with attention to contraindications and potential drug interactions.